Drug intelligence / Profile preview

CMR215

Development stage: Preclinical
Lead developer: Scripps Research
Modality: Small Molecules

Overview

CMR215 is a small molecule drug that acts as an agonist of the STING (Stimulator of Interferon Genes) pathway. It was initially developed by The Scripps Research Institute and is being advanced in the field of immuno-oncology, with a primary focus on non-muscle invasive bladder neoplasms. The drug's mechanism involves activating the STING pathway, which plays a key role in innate immune responses and has potential applications in cancer therapy by stimulating anti-tumor immunity. As of March 2025, its highest development status is preclinical.

Other names: CMR-215CMR215CMR 215

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on CMR215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMR215.

Explore the full profile